--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About CTMX20260220C6
Pharmaceutical
CytomX Therapeutics, Inc., was incorporated in Delaware in September 2010. The Company is a clinical-stage, oncology-focused biopharmaceutical company focused on the development of novel conditionally activated biologics designed to target the tumor microenvironment. The Company's proprietary, multifunctional, multimodal PROBODY technology platform is designed to enable conditional activation of biotherapeutic drug candidates within tumor microcycles while minimizing drug activity in healthy tissues and circulation.
